ELTS评分对儿童慢性髓系白血病慢性期生存结局的预测作用
单中心回顾性队列研究纳入216例CML-CP患儿,按ELTS评分分为低危145例、中危52例、高危19例,中高危组6年FFS、PFS、EFS均显著低于低危组,但6年OS无显著差异。多因素分析显示ELTS评分是FFS和PFS的独立影响因素。
要点
- ELTS评分可对儿童CML-CP进行风险分层,中高危组治疗失败和疾病进展风险更高。
- 中高危组与低危组6年OS无显著差异,ELTS评分对OS预测作用有限。
- ELTS评分是FFS(HR=1.97)和PFS(HR=2.95)的独立影响因素。
核心结论
- ELTS评分有助于儿童CML-CP的预后风险分层。
- 中高危组较低危组更易出现治疗失败和疾病进展。
- ELTS评分对OS的预测作用有限。
研究设计与样本
- 单中心回顾性队列研究,纳入北京大学人民医院2010年1月至2023年12月收治的216例CML-CP患儿。
- 按ELTS评分分为低危组145例、中危组52例、高危组19例。
- 采用Kaplan-Meier法和Log-Rank检验进行生存分析,Cox回归模型分析预后因素。
主要发现
- 216例患儿中男122例、女94例,诊断年龄11.0(8.0,14.7)岁,随访时间77(57,99)个月。
- 低危组与中高危组6年FFS分别为(83.0±3.1)%和(64.6±5.7)%,差异有统计学意义(χ²=9.45,P=0.002)。
- 低危组与中高危组6年PFS分别为(91.4±2.3)%和(78.7±4.8)%,差异有统计学意义(χ²=7.16,P=0.007)。
- 低危组与中高危组6年EFS分别为(80.8±3.3)%和(64.2±5.7)%,差异有统计学意义(χ²=7.40,P=0.007)。
- 低危组与中高危组6年OS分别为(98.5±1.0)%和(95.6±2.4)%,差异无统计学意义(χ²=0.35,P=0.550)。
关键数值与推荐
- 多因素分析显示ELTS评分是FFS的独立影响因素(HR=1.97,95%CI 1.11~3.49)。
- 多因素分析显示ELTS评分是PFS的独立影响因素(HR=2.95,95%CI 1.18~7.39)。
- 未发现EFS和OS的独立影响因素。
临床怎么用
- 初诊时可采用ELTS评分对儿童CML-CP进行风险分层,识别中高危患儿。
- 中高危组患儿应加强治疗失败和疾病进展的监测与干预。
- ELTS评分对OS预测能力有限,OS评估需结合其他因素。
局限性
- 本研究为单中心回顾性队列研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the predictive effect of European treatment and outcome study long term survival (ELTS) score on survival outcomes in chronic myeloid leukemia of chronic phase (CML-CP) children. Methods: A single-center retrospective cohort study was conducted. Clinical data of 216 children with CML-CP in Peking University People's Hospital from January 2010 to December 2023 were analyzed. Children were divided into low, intermediate and high-risk groups according to ELTS score. The survival outcomes and prognostic factors were analyzed. Kaplan-Meier method and Log-Rank test were used for survival analysis.Cox regression model was applied for analysis of prognostic factors. Results: Among the 216 children with CML-CP, there were 122 males and 94 females, with the diagnosis age of 11.0 (8.0, 14.7) years. The follow-up time was 77 (57, 99) months. According to ELTS score, 145, 52, and 19 children were classified as low, intermediate and high-risk group. For the low-risk and intermediate/high-risk groups, the 6-year failure-free survival (FFS) rates were (83.0±3.1)% and (64.6±5.7)%, the 6-year progression-free survival (PFS) rates were (91.4±2.3)% and (78.7±4.8)%, and the 6-year event-free survival (EFS) rates were (80.8±3.3)% and (64.2±5.7)%, with statistically significant difference (χ2=9.45, 7.16, 7.40, P=0.002, 0.007, 0.007), respectively.The 6-year overall survival (OS) rates were (98.5±1.0)% and (95.6±2.4)%, without statistically significant difference (χ2=0.35, P=0.550). Multivariate analysis showed that ELTS score was an independent prognostic factor or tendency for FFS (HR=1.97, 95%CI 1.11-3.49), PFS (HR=2.95, 95%CI 1.18-7.39), and no independent prognostic factor for EFS and OS were found. Conclusions: ELTS score at diagnosis can help stratify the risk of children with CML-CP. The children in intermediate/high-risk group are more likely to have treatment failure, disease progression than those in low-risk group, but the predictive ability of ELTS score for OS is limited. 目的: 探讨欧洲治疗与预后研究长期生存(ELTS)评分对慢性髓系白血病慢性期(CML-CP)患儿生存结局的预测作用。 方法: 回顾性队列研究。分析2010年1月至2023年12月北京大学人民医院收治的216例CML-CP患儿的临床资料。根据ELTS评分分为低危组、中危组、高危组。分析患儿生存结局情况及其影响因素。采用Kaplan-Meier法绘制生存曲线并用Log-Rank检验进行比较,Cox回归模型进行预后相关因素分析。 结果: 216例CML-CP患儿中男122例、女94例,诊断年龄11.0(8.0,14.7)岁。随访时间77(57,99)个月。按照ELTS评分,低危组145例、中危组52例、高危组19例。低危组、中高危组患儿的6年无失败生存率(FFS)分别为(83.0±3.1)%和(64.6±5.7)%、6年无进展生存率(PFS)分别为(91.4±2.3)%和(78.7±4.8)%、6年无事件生存率(EFS)分别为(80.8±3.3)%和(64.2±5.7)%,组间比较差异均有统计学意义(χ²=9.45、7.16、7.40,P=0.002、0.007、0.007),6年总生存率(OS)分别为(98.5±1.0)%和(95.6±2.4)%,组间比较差异无统计学意义(χ²=0.35,P=0.550)。多因素分析显示,ELTS评分是FFS(HR=1.97,95%CI 1.11~3.49)、PFS(HR=2.95,95%CI 1.18~7.39)的独立影响因素,未发现EFS、OS的独立影响因素。 结论: ELTS评分有助于儿童CML-CP的疾病预后风险分层,ELTS评分中高危组较低危组更易出现治疗失败、疾病进展,但ELTS评分对OS的预测作用较小。.
引用
- Zheng FY, Deng RZ, Lu AD, et al. [Analysis of predictive effect of European treatment and outcome study long term survival score on survival outcomes in children with chronic myeloid leukemia of chronic phase]. Zhonghua Er Ke Za Zhi. 2024. PMID: 39327962. doi:10.3760/cma.j.cn112140-20240130-00085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。